Analytical Data
-
基因名
HLA-A*33:03&B2M&EGFR(HVKITDFGR) Monomer
- Application
-
别名
HLA-A*3303 & B2M & EGFR(HVKITDFGR)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA79865.1 (G25-T305)&P61769
-
表达区间
AAA79865.1 (G25-T305)&P61769 (I21-M119)&HVKITDFGR
-
分子量
40-43 kDa and 13 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*33:03, a specific human leukocyte antigen (HLA) class I molecule, is critical for understanding immune response and disease association, particularly in the context of autoimmune disorders and transplant compatibility. HLA molecules present peptides to CD8+ T cells, enabling immune surveillance. The focus on the HLA-A*33:03 variant, along with its beta-2-microglobulin (B2M) component and the epidermal growth factor receptor (EGFR) peptide HVKITDFGR, offers insights into peptide-binding characteristics and T cell recognition. Recombinant protein production of the HLA-A*33:03-B2M-EGFR complex facilitates structural studies and functional assays to elucidate the implications of this specific HLA variant in oncogenic processes. By investigating the interactions between this monomeric protein and its potential T cell targets, researchers can enhance the understanding of tumor immunology and contribute to the development of immunotherapies that leverage HLA-A*33:03 for targeted treatments in cancers expressing EGFR. This lines up with the increasing relevance of tailored immunotherapy, particularly in cancers where HLA-A*33:03 plays a role, thereby providing important data for clinical applications.
